Impact of Prior Therapy for Diabetic Macular Edema (DME) on Visual and Anatomic Outcomes Following Treatment with Intravitreal Aflibercept: Results from the Phase 3 VISTA-DME and VIVID-DME Studies

被引：0
|
作者：
Quan Dong Nguyen [1 ]
机构：
[1] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA
来源：
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE | 2014年 / 55卷 / 13期
关键词：
499 diabetic retinopathy; 466 clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials; 748 vascular endothelial growth factor;
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
5055
引用
收藏
页数：2
相关论文
共 41 条
  • [31] EFFICACY, DURABILITY, AND SAFETY OF FARICIMAB IN DIABETIC MACULAR EDEMA (DME): 1-YEAR RESULTS FROM THE PHASE 3 YOSEMITE AND RHINE TRIALS
    Cooper, B.
    Haskova, Z.
    Silverman, D.
    Ives, J.
    Basu, K.
    Lin, H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A51 - A51
  • [32] Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials
    Wells, John A.
    Wykoff, Charles Clifton
    Willis, Jeffrey R.
    Haskova, Zdenka
    Lin, Hugh
    Silverman, David
    Adamis, Anthony P.
    Ives, Jane
    Abreu, Francis
    Basu, Karen
    Tadayoni, Ramin
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2021, 62 (08)
  • [33] Effect of Baseline Hemoglobin A1c (HbA1c) and On-Treatment Blood Pressure (BP) on Visual Outcomes in Patients with Diabetic Macular Edema (DME) Receiving Intravitreal Aflibercept Injection (IAI) or Laser Treatment
    Wykoff, Charles C.
    DIABETES, 2015, 64 : A76 - A76
  • [34] Efficacy, durability, and safety of faricimab in diabetic macular edema (DME): 1-year results from China subpopulation of phase 3 RHINE trial
    Sun, Xiaodong
    Li, Xiaorong
    Han, Mei
    Idowu, Oluwatobi
    Jiang, Qin
    Lai, Chi-Chun
    Liu, Ruyuan
    Liu, Wenxin
    Liu, Xiaoling
    Tang, Yannan
    Wang, Yanling
    Willis, Jeffrey
    Wu, Zhifeng
    Ye, Jian
    Zhang, Li
    Kotecha, Aachal
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [35] Port Delivery System with ranibizumab (PDS) stabilizes retinal nonperfusion and macular leakage: results from Pagoda and Pavilion phase 3 trials in diabetic macular edema (DME) and diabetic retinopathy (DR)
    Wirthlin, Robert
    Gill, Manjot
    Howard, Dena
    Menezes, Alicia
    Rahman, Salman
    Latkany, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
  • [36] Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment Outcomes from the Phase 3 Program
    Do, Diana V.
    Quan Dong Nguyen
    Vitti, Robert
    Berliner, Alyson J.
    Gibson, Andrea
    Saroj, Namrata
    Soo, Yuhwen
    Boyer, David S.
    OPHTHALMOLOGY, 2016, 123 (04) : 850 - 857
  • [37] The use of intravitreal implant ILUVIEN ® (fluocinolone acetonide) after prior OZURDEX ® Implant (DEX) (Dexamathason) in patients with diabetic macular edema (DME) - Efficacy and safety outcomes from the University Eye Clinic in Frankfurt, Germany
    Singh, Pankaj
    Chedid, Adonis
    Deuchler, Svenja
    Kohnen, Thomas
    Mueller, Michael
    Koch, Frank H. J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [38] Real-world outcomes with ranibizumab 0.5 mg treatment in French patients with visual impairment due to diabetic macular edema: 12-month results from the 36-month BOREAL-DME study
    Garcher, Catherine P. Creuzot
    Massin, Pascale
    Kodjikian, Laurent
    Girmens, Jean-Francois
    DelCourt, Cecile
    Fajnkuchen, Frank
    Glacet, Agnes
    Guillausseau, Pierre-Jean
    Derveloy, Audrey
    Finzi, Laetitia
    Blin, Patrick
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2017, 58 (08)
  • [39] Real-World Outcomes with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema: 12-Month Results from the 36-Month BOREAL-DME Study
    Massin, Pascale
    Creuzot-Garcher, Catherine
    Kodjikian, Laurent
    Girmens, Jean-Francois
    Delcourt, Cecile
    Fajnkuchen, Frank
    Glacet-Bernard, Agnes
    Guillausseau, Pierre-Jean
    Ponthieux, Anne
    Blin, Patrick
    Grelaud, Angela
    OPHTHALMIC RESEARCH, 2019, 62 (02) : 101 - 110
  • [40] Outcomes of patients with diabetic macular edema (DME) and baseline best corrected visual acuity (BCVA) of 20/50 or worse or 20/40 or better who were treated with aflibercept 8 mg and 2 mg: a post hoc analysis of the phase 2/3 PHOTON trial
    Adrean, Sean
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2024, 65 (07)
12345